

Avenue Therapeutics, Inc.  
1111 Kane Concourse, Suite 301  
Bay Harbor Islands, Florida 33154

VIA EDGAR

October 24, 2023

Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Joshua Gorsky

**Re: Avenue Therapeutics, Inc.  
Registration Statement on Form S-1 (Reg. No. 333-274562)  
Request for Acceleration of Effective Date**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the "**Company**") hereby requests that the Securities and Exchange Commission (the "**Commission**") accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the "**Registration Statement**") so that the Registration Statement will be declared effective as of 5:30 p.m. Eastern time, on October 25, 2023. The Company hereby authorizes Rakesh Gopalan or David Wolpa, both of whom are attorneys at the Company's outside legal counsel, McGuireWoods LLP, to orally modify or withdraw this request for acceleration.

Once the Registration Statement has been declared effective, please orally confirm that event with Mr. Gopalan at (704) 343-2275 or Mr. Wolpa at (704) 343-2185.

Thank you for your assistance in this matter.

Very truly yours,

Avenue Therapeutics, Inc.

*/s/ Alexandra MacLean*

Name: Alexandra MacLean

Title: Chief Executive Officer

cc (via email): Rakesh Gopalan and David Wolpa, McGuireWoods LLP  
Barry Grossman, Sarah Williams, Matthew Bernstein, Ellenoff Grossman & Schole LLP  
Eric Cheng, Maxim Group LLC

---